Oral corticosteroids in asthma and beyond: moving forward

Jeffrey  Shi Kai Chan; Ruth B Murray; David Price

doi:10.1183/13993003.00776-2022

Oral corticosteroids in asthma and beyond: moving forward

Jeffrey Shi Kai Chan, Ruth B Murray, David Price^* (Corresponding Author)

^*Corresponding author for this work

Research output: Contribution to journal › Editorial › peer-review

3 Citations (Scopus)

1 Downloads (Pure)

Abstract

As some of the earliest-known and most effective anti-inflammatory agents, corticosteroids have long been a part of the physicians’ armamentarium against asthma and other chronic inflammatory conditions. While inhaled corticosteroids (ICS) are the cornerstone of asthma therapy, both the Global Initiative for Asthma (GINA) and British Thoracic Society/Scottish Intercollegiate Guidelines Network (BTS/SIGN) guidelines recommended the use of oral corticosteroids (OCS) as intermittent therapy in severe acute asthmatic attacks and as maintenance therapy in selected patients with severe asthma refractory to inhaled therapies [1, 2]. More recently, OCS have also been recommended as an adjunct to biologic therapies

Original language	English
Article number	2200776
Number of pages	5
Journal	European Respiratory Journal
Volume	60
Issue number	3
Early online date	15 Sept 2022
DOIs	https://doi.org/10.1183/13993003.00776-2022
Publication status	Published - 15 Sept 2022

Access to Document

10.1183/13993003.00776-2022Licence: Unspecified

Chan_etal_ERJ_Oral_Corticosteroids_In_AAM
This is an author-submitted, peer-reviewed version of a manuscript that has been accepted for publication in the European Respiratory Journal, prior to copy-editing, formatting and typesetting. This version of the manuscript may not be duplicated or reproduced without prior permission from the European Respiratory Society. The publisher is not responsible or liable for any errors or omissions in this version of the manuscript or in any version derived from it by any other parties. The final, copy-edited, published article, which is the version of record, is available without a subscription 18 months after the date of issue publication.
Accepted author manuscript, 189 KBLicence: Unspecified

Cite this

@article{6b62612395514d469832f5d4b4ef4334,

title = "Oral corticosteroids in asthma and beyond: moving forward",

abstract = "As some of the earliest-known and most effective anti-inflammatory agents, corticosteroids have long been a part of the physicians{\textquoteright} armamentarium against asthma and other chronic inflammatory conditions. While inhaled corticosteroids (ICS) are the cornerstone of asthma therapy, both the Global Initiative for Asthma (GINA) and British Thoracic Society/Scottish Intercollegiate Guidelines Network (BTS/SIGN) guidelines recommended the use of oral corticosteroids (OCS) as intermittent therapy in severe acute asthmatic attacks and as maintenance therapy in selected patients with severe asthma refractory to inhaled therapies [1, 2]. More recently, OCS have also been recommended as an adjunct to biologic therapies",

author = "{Shi Kai Chan}, Jeffrey and Murray, {Ruth B} and David Price",

year = "2022",

month = sep,

day = "15",

doi = "10.1183/13993003.00776-2022",

language = "English",

volume = "60",

journal = "European Respiratory Journal",

issn = "0903-1936",

publisher = "European Respiratory Society",

number = "3",

}

TY - JOUR

T1 - Oral corticosteroids in asthma and beyond

T2 - moving forward

AU - Shi Kai Chan, Jeffrey

AU - Murray, Ruth B

AU - Price, David

PY - 2022/9/15

Y1 - 2022/9/15

N2 - As some of the earliest-known and most effective anti-inflammatory agents, corticosteroids have long been a part of the physicians’ armamentarium against asthma and other chronic inflammatory conditions. While inhaled corticosteroids (ICS) are the cornerstone of asthma therapy, both the Global Initiative for Asthma (GINA) and British Thoracic Society/Scottish Intercollegiate Guidelines Network (BTS/SIGN) guidelines recommended the use of oral corticosteroids (OCS) as intermittent therapy in severe acute asthmatic attacks and as maintenance therapy in selected patients with severe asthma refractory to inhaled therapies [1, 2]. More recently, OCS have also been recommended as an adjunct to biologic therapies

AB - As some of the earliest-known and most effective anti-inflammatory agents, corticosteroids have long been a part of the physicians’ armamentarium against asthma and other chronic inflammatory conditions. While inhaled corticosteroids (ICS) are the cornerstone of asthma therapy, both the Global Initiative for Asthma (GINA) and British Thoracic Society/Scottish Intercollegiate Guidelines Network (BTS/SIGN) guidelines recommended the use of oral corticosteroids (OCS) as intermittent therapy in severe acute asthmatic attacks and as maintenance therapy in selected patients with severe asthma refractory to inhaled therapies [1, 2]. More recently, OCS have also been recommended as an adjunct to biologic therapies

U2 - 10.1183/13993003.00776-2022

DO - 10.1183/13993003.00776-2022

M3 - Editorial

SN - 0903-1936

VL - 60

JO - European Respiratory Journal

JF - European Respiratory Journal

IS - 3

M1 - 2200776

ER -

Oral corticosteroids in asthma and beyond: moving forward

Abstract

Access to Document

Fingerprint

Cite this